3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
12
Phase NA
10
Phase 3
10
Phase 2/3
3
Phase 1/2
2
Phase 4
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
49
Neoplasms
36
Prostatic Neoplasms
25
Carcinoma, Non-Small-Cell Lung
25
Polycystic Ovary Syndrome
16
Pain
15
Keratosis, Actinic
14
Leukemia
12
Colorectal Neoplasms
11
Uterine Cervical Neoplasms
10
Pancreatic Neoplasms
10
Lung Neoplasms
10
Leiomyoma
10
Carcinoma, Hepatocellular
10
Ovarian Neoplasms
9
Neoplasm Metastasis
9
Lymphoma, Follicular
9
Carcinoma, Renal Cell
9
Brain Neoplasms
9
Neuroendocrine Tumors
8
Arthritis, Rheumatoid
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Melanoma
7
Kidney Neoplasms
7
Head and Neck Neoplasms
7
Colonic Neoplasms
7
Cancer Pain
7
Multiple Myeloma
6
Lymphoma
6
Liver Neoplasms
6
Interventions
dolasetron
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
alizapride
1
Tropisetron
1
Ondansetron
1
Metoclopramide
1
Granisetron
1
Dexamethasone
1
Calcium Dobesilate
1
Aprepitant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Has results
×
Nausea
×
Clear all
NCT01636947
2018-09-25
KMEC
Merck Sharp & Dohme LLC
Phase 4
Completed
494 enrolled
14 charts